Novartis AG ADR (NVS)vsSotera Health Co (SHC)
NVS
Novartis AG ADR
$153.12
-0.17%
HEALTHCARE · Cap: $289.19B
SHC
Sotera Health Co
$15.74
+0.32%
HEALTHCARE · Cap: $4.62B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 4658% more annual revenue ($56.58B vs $1.19B). NVS leads profitability with a 23.9% profit margin vs 9.9%. SHC appears more attractively valued with a PEG of 1.68. SHC earns a higher WallStSmart Score of 68/100 (B-).
NVS
Hold49
out of 100
Grade: D+
SHC
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.6%
Fair Value
$91.58
Current Price
$153.12
$61.54 premium
Intrinsic value data unavailable for SHC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Strong operational efficiency at 31.3%
Earnings expanding 175.4% YoY
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SHC
The strongest argument for SHC centers on Operating Margin, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : SHC
The primary concerns for SHC are PEG Ratio, P/E Ratio, Free Cash Flow. Debt-to-equity of 3.65 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a declining stock while SHC is a value play — different risk/reward profiles.
SHC carries more volatility with a beta of 1.80 — expect wider price swings.
SHC is growing revenue faster at 10.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
SHC scores higher overall (68/100 vs 49/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Sotera Health Co
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?